Loading...

Follow Fans for the Cure on Feedspot

Continue with Google
Continue with Facebook
or

Valid

There is a new initiative in prostate cancer research that promises to make a significant impact in our fight against prostate cancer. Listen to Dr. Eli Van Allen’s play-by-play on the Metastatic Prostate Cancer Project, a game-changing initiative to advance precision prostate cancer medicine. FANS for the CURE Board, Chairman Steve Garvey and Dr. Van Allen talk baseball and how the Metastatic Prostate Cancer Project will bring new insights to fuel a new era of prostate cancer research.

Dr. Eli Van Allen is a clinical computational oncologist and prostate cancer researcher at Dana-Farber Cancer Institute. An Associate Member of the Broad Institute of MIT and Harvard, he leads the Metastatic Prostate Cancer Project, which is being conducted by the Broad Institute in collaboration with Dana-Farber.

Read more about FANS for the CURE’s partnership with Dr. Van Allen and the Metastatic Prostate Cancer Project here.

The post A New Inning for Prostate Cancer Research > Listen to Dr. Eli Van Allen talk with Steve Garvey and the FANS board appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

This content is password protected. To view it please enter your password below:

Password:

The post Protected: FANS MVP: Nick Castellanos appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Time to bid on two amazing Delta Suite tickets to watch the New York Yankees play the Baltimore Orioles on Thursday, March 28, at Yankee Stadium for Opening Day!

Bid now on our Charitybuzz page.

The post AUCTION ALERT > 2 Delta Suite Tickets for New York Yankees vs Baltimore Orioles appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

The Metastatic Prostate Cancer Project (MPCproject.org) has released the first of many publicly available datasets to come from this  nationwide genomic research initiative designed for men with advanced or metastatic prostate cancer. Comprised of clinical, genomic and patient reported data from 19 patient-partners, the data has been shared in cBioPortal, a public scientific portal, as an initial step toward the development of a much larger and more comprehensive dataset.  You can read more about and link to the data here MPCproject.org/data-release.

MPCP is being conducted at the Broad Institute of MIT and Harvard in collaboration with Dana-Farber Cancer Institute, and it takes a new approach to genomic research by working directly with men with advanced and metastatic prostate cancer. When patients sign up for the project, they provide information about their experiences with their disease and where they have been seen for treatment. In addition, patients provide their medical records as well as tissue and/or blood samples for genomic analysis. The goal of MCPC is to create the most comprehensive prostate cancer database that will be shared with the entire research community and enable scientists to look at patient-provided, de-identified data, tumor samples, clinical information and more — allowing for more exhaustive research into prostate cancer and its treatment.

Data will continue to be released as it is generated so that the entire research community can have access to it. As the dataset gets larger, researchers will be able to gain more insights. This means that the more men that participate in the project, the more successful it will be. If you have metastatic or advanced prostate cancer, please join the 650+ men who already signed up to participate. Every man makes a difference, so get counted.

In February 2019, FANS for the CURE announced our ongoing partnership with MPCP. We are proud to support the entire MPCP team and this game changing initiative to accelerate discoveries and better treatments for prostate cancer. Plays like this will help win the war against prostate cancer. Take a moment and GET COUNTED!

The post Metastatic Prostate Cancer Project Announces First Data Release appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
The New York Stock Exchange welcomes Fans for the Cure. CEO and Founder Ed Randall, joined by Chris Taylor, Vice President, Listings and Services, rings The Opening Bell®.

Never a dull moment for FANS for the CURE Founder and CEO, Ed Randall. For over 15 years, FANS for the CURE has delivered the message of prostate cancer awareness, education and early detection to over 1 million sports fans. 2019 is getting off to an incredible start and we’re looking forward to making a positive impact on men and families everywhere. Help us make plays that count – JOIN THE TEAM.

The New York Stock Exchange welcomes Fans for the Cure. CEO and Founder Ed Randall, joined by Chris Taylor, Vice President, Listings and Services, rings The Opening Bell®. The New York Stock Exchange welcomes Fans for the Cure. CEO and Founder Ed Randall, joined by Chris Taylor, Vice President, Listings and Services, rings The Opening Bell®.

The post Ed Randall Rings the NYSE Opening Bell appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

In 1949, Brooklyn Dodgers pitcher Preacher Roe found himself in a jam. Facing the rival Boston Braves with the score tied 1-1, the first two batters of the inning had singled and were now on first and second. Worse, he had just given up hits to the opposing pitcher, the poorest hitter on the team, and the notorious Eddie Stanky, whose questionable baserunning tactics were well known around the league. Roe took a moment to contemplate, checked the runners, and delivered the pitch. As he followed through, the sharp crack of the bat and arc of the ball speeding into left field quickly worsened the situation. The runners rounded the bases, looking to score. Roe was going to need some help.

And help he would get. The left fielder Gene Hermanski, sprinting towards the infield, made an incredible shoestring catch. Leaping to his feet, he threw to second baseman Jackie Robinson, who stepped on the bag and relayed the ball to first baseman Gil Hodges to complete an inning-ending triple play, one of the rarest events in baseball. In mere seconds, with the help of his teammates, the fortunes of Roe had gone from bad, to worse, to excellent. Roe would go on to give up only one more run, and the Dodgers would win the game, 5-2.

Men with newly diagnosed prostate cancer encounter a similar plight. Not only are they presented with a cancer diagnosis that threatens mortality, they are also faced with the possibility of sexual and urinary impairment after treatment. To achieve the best outcomes, all three of these factors must be addressed and, more importantly, the patient must be satisfied with all three outcomes. This is no facile endeavor and, much like the triple play, requires expert coordination to achieve each goal. The treatment team is integral in achieving the first outcome, getting and keeping the patient cancer-free. Today the team may include surgeons, medical and radiation oncologists, nurses, and researchers. It may also include specialists to facilitate the other two outcomes, such as a men’s health specialist for sexual function, and a pelvic floor therapist for urinary function. And finally, the support of family, friends, and other cancer survivors is crucial for long-term well-being.

Different treatments impact these three outcomes differently, so it is important for patients to understand which factors are most important to them and the likelihood of achieving each outcome. Today, preference assessment and long-term outcomes data combine to create a powerful tool to enhance decision-making. No longer must men rely on only a general sense of their individual goals; now they are able to better estimate of the probability of realizing one, two, or three of the key outcomes: cancer cure, sexual function, and urinary health.

As a parallel, consider the following: In 1949, Roe knew he was in trouble, and probably knew the other team had a good chance of scoring. But today, with the help of advanced statistics, we know more. We know that there was a 44% chance of a run scoring before the triple play, and that the Dodgers had a 40% chance of winning at that point, a 44% chance if one out was made, a 50% chance if two outs were made, and a 56% chance after the incredible triple play.

Similarly, men can now know their chance of cure, sexual function, and urinary control after any treatment based on a variety of factors. Using these factors, we may say that a 65-year-old man with intermediate-risk prostate cancer considering a robotic radical prostatectomy has a 95% chance of cure, a 90% chance of regaining continence, and a 50% chance of regaining baseline sexual function—if he is treated in a center of excellence. These numbers change based on treatment and the individual characteristics of each patient. Advanced statistics and analysis such as this permit men to choose the best treatment for them based on their own preferences and goals.

A well-rounded team, with an assist from years of data and advanced statistics, can be a winning combination in baseball and in prostate cancer. When proficient teams aptly deploy these tools, patients with prostate cancer are more likely to attain cure, urinary control, and sexual function. This is the ultimate triple play.

Joseph D. Shirk, MD
Mark S. Litwin, MD, MPH

UCLA Department of Urology

Joseph D. Shirk, MD, UCLA Department of Urology Mark S. Litwin, MD, MPH, UCLA Department of Urology

The post Optimizing Outcomes for Men with Prostate Cancer: A Triple Play appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

An estimated one in nine men will be diagnosed with prostate cancer in his lifetime, with nearly 175,000 new cases expected in 2019. Stats like these are what drive our mission at Fans for the Cure: to save men’s lives by promoting awareness around prostate cancer, testing and treatment, and by supporting prostate cancer research. As part of these efforts, we are serving as an Advocacy Partner for the Metastatic Prostate Cancer Project (MPCP) — a nationwide genomic research initiative designed for men with advanced or metastatic prostate cancer. And we couldn’t be more excited about the partnership and what MPCP is doing to advance prostate cancer research.

This cutting-edge project, which is being conducted at the Broad Institute of MIT and Harvard in collaboration with Dana-Farber Cancer Institute, takes a new approach to genomic research by working directly with men with advanced and metastatic prostate cancer to accelerate important discoveries. The goal of MCPC is to create the most comprehensive prostate cancer database that will be shared with the entire research community and enable scientists to look at patient-provided, de-identified data, tumor samples, clinical information and more — allowing for more exhaustive research into prostate cancer and its treatment.

Illumina Novo 6000 Genomic Sequenders. Broad Institute, Cambridge, MA

A NEW FRONTIER FOR PROSTATE CANCER RESEARCH

Like all cancers, prostate cancer is not a singular disease with one cause and one treatment. Each tumor, each patient holds a piece of the puzzle. MPCP seeks to gather as many pieces of this puzzle by inviting men around the country to anonymously share their tissues and medical information directly with researchers who are looking for more targeted therapies. So, regardless of your location, if you have advanced or metastatic prostate cancer or a history of advanced or metastatic prostate cancer, you can participate in research for better treatments and, ultimately, a cure.

Dr. Eliezer Van Allen and the Metastatic Prostate Cancer Project / Count Me In team

Leading the MPCP charge is Eliezer Van Allen, medical oncologist at Dana-Farber Cancer Institute and associate member of the Broad Institute specializing in computational cancer genomics and personalized cancer therapeutics. “What makes the Metastatic Prostate Cancer Project so exciting is how accessible it is for patients and, as a result, how fruitful it can be for researchers,” Van Allen said. “Prostate cancer is more common than many people realize, and yet few men have had the ability to contribute their tumor samples and clinical data to research, largely because they did not have a way of doing so — until now.” Since MPCP’s launch in early 2018, more than 633 men and counting are participating in the project.

GET COUNTED AND MAKE A DIFFERENCE

“Participating in MPCP is an extraordinary opportunity for men with advanced or metastatic prostate cancer to make a profound contribution in the fight against prostate cancer,” said Ed Randall, Founder and CEO of Fans for the Cure. “With its patient-driven focus and use of big data, MPCP is a game-changing initiative that will lead to a deeper understanding of prostate cancer and significant benefits for men and the families that love them.”

Metastatic Prostate Cancer Project / Count Me In kits

The project is associated with Count Me In, a nonprofit organization that is changing the future of cancer by bringing together researchers and patients living with all major and rare cancer types. Count Me In and the Metastatic Prostate Cancer Project are funded in part by the Biden Cancer Initiative and Emerson Collective. Fans for the Cure will be sharing more exciting news about the Metastatic Prostate Cancer Project in the months ahead. In the meantime, GET COUNTED!

The post Fans for the Cure Partners with the Metastatic Prostate Cancer Project to Accelerate Prostate Cancer Research appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

YOU ARE INVITED to a spectacular evening at The Edison Ballroom with honorees Phil Simms, Joseph Abboud, and Dr. James McKiernan. Help support our fight against prostate cancer. Register here.

The post SAVE THE DATE: All-Star Celebration Dinner, June 11, 2019 appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

This content is password protected. To view it please enter your password below:

Password:

The post Protected: Fans for the Cure Partners with the Metastatic Prostate Cancer Project to Accelerate Prostate Cancer Research appeared first on Fans for the Cure.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Get them while they’re hot! Fans for the Cure invites you to bid on some amazing golf packages for five of the most enjoyable courses in the country. But you better do it soon, because time is running out. The auction ends Wednesday, February 13, and is a perfect Valentine’s Day gift to conquer those winter blues. Find a variety of golf packages and other amazing experiences (host an XM radio show anyone?) at our Fans for the Cure/Charitybuzz auction page. Good luck!

The post AUCTION ALERT: ONLY DAYS LEFT TO BID ON GOLF PACKAGES, BASEBALL GAMES, AND OTHER UNIQUE EXPERIENCES appeared first on Fans for the Cure.

Read Full Article

Read for later

Articles marked as Favorite are saved for later viewing.
close
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview